Orbiton Theragnostics provides integrated theranostic solutions for nuclear medicine companies and precision cancer care. The organization offers preclinical and clinical study services, including in‑vitro and in‑vivo studies, animal imaging, biodistribution, toxicity, and first‑in‑human clinical studies. It delivers contract research and technology transfer CDMO services for radiopharmaceutical formulation, radiolabeling, and analytical method development. Orbiton also supports isotope manufacturing and supply for clinical trials, covering isotope formulations, dispensing, and radioactive drug manufacturing. In addition, it develops proprietary theranostic agents that combine diagnostics and therapy.
